Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Total Debt (2016 - 2024)

Historic Total Debt for Capricor Therapeutics (CAPR) over the last 16 years, with Q3 2024 value amounting to $3.4 million.

  • Capricor Therapeutics' Total Debt changed 0.0% to $3.4 million in Q3 2024 from the same period last year, while for Sep 2024 it was $3.4 million, marking a year-over-year change of 0.0%. This contributed to the annual value of $3.4 million for FY2023, which is 257.49% down from last year.
  • As of Q3 2024, Capricor Therapeutics' Total Debt stood at $3.4 million, which was down 0.0% from $3.4 million recorded in Q2 2024.
  • Capricor Therapeutics' Total Debt's 5-year high stood at $4.0 million during Q4 2021, with a 5-year trough of $3.4 million in Q1 2020.
  • Moreover, its 5-year median value for Total Debt was $3.4 million (2020), whereas its average is $3.5 million.
  • Its Total Debt has fluctuated over the past 5 years, first soared by 1775.3% in 2021, then plummeted by 1407.53% in 2023.
  • Over the past 5 years, Capricor Therapeutics' Total Debt (Quarter) stood at $3.4 million in 2020, then increased by 17.75% to $4.0 million in 2021, then fell by 12.83% to $3.5 million in 2022, then dropped by 2.57% to $3.4 million in 2023, then changed by 0.0% to $3.4 million in 2024.
  • Its Total Debt stands at $3.4 million for Q3 2024, versus $3.4 million for Q2 2024 and $3.4 million for Q1 2024.